Dr Reddy's Plans Relaunch of Generic Semaglutide and US Biosimilar Launch
Dr Reddy's domestic formulations business grew in the September quarter, offset by declines in Revlimid sales in North America and weakness in the API segment. The company plans to relaunch generic semaglutide in November 2026, targeting six to seven million pens initially, with a longer-term annual opportunity of 12-15 million pens. Additionally, it anticipates launching the abatacept biosimilar in the US following a regulatory decision expected in December 2026. Earnings are projected to decline in FY27 before potential recovery in FY28, driven by these product launches and domestic growth.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 37/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 25 Oct, 07:58 pm. Other outlets followed.
- 1